A detailed history of Candriam S.C.A. transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 713,092 shares of RARE stock, worth $32.4 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
713,092
Previous 688,942 3.51%
Holding current value
$32.4 Million
Previous $28.3 Million 39.9%
% of portfolio
0.23%
Previous 0.17%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$40.21 - $59.36 $971,071 - $1.43 Million
24,150 Added 3.51%
713,092 $39.6 Million
Q2 2024

Aug 05, 2024

BUY
$37.42 - $51.61 $6.41 Million - $8.84 Million
171,345 Added 33.1%
688,942 $28.3 Million
Q1 2024

May 03, 2024

BUY
$43.02 - $53.69 $15.9 Million - $19.8 Million
369,117 Added 248.6%
517,597 $24.2 Million
Q4 2023

Feb 14, 2024

BUY
$31.73 - $49.19 $3.14 Million - $4.87 Million
99,000 Added 200.08%
148,480 $7.1 Million
Q2 2023

Aug 08, 2023

SELL
$37.35 - $52.15 $416,639 - $581,733
-11,155 Reduced 18.4%
49,480 $2.28 Million
Q1 2023

May 12, 2023

BUY
$36.99 - $48.71 $412,623 - $543,360
11,155 Added 22.54%
60,635 $2.43 Million
Q2 2021

Jul 20, 2021

SELL
$92.19 - $115.71 $4.51 Million - $5.66 Million
-48,949 Reduced 49.73%
49,480 $4.72 Million
Q4 2020

Jan 22, 2021

BUY
$84.4 - $177.39 $8.31 Million - $17.5 Million
98,429 New
98,429 $13.6 Million
Q2 2020

Jul 23, 2020

SELL
$46.91 - $78.22 $5.7 Million - $9.5 Million
-121,500 Closed
0 $0
Q4 2019

Jan 21, 2020

SELL
$36.08 - $45.83 $685,520 - $870,770
-19,000 Reduced 13.52%
121,500 $5,000
Q3 2019

Oct 21, 2019

BUY
$42.5 - $63.11 $637,500 - $946,650
15,000 Added 11.95%
140,500 $6,000
Q2 2019

Aug 01, 2019

BUY
$54.93 - $74.36 $549,300 - $743,600
10,000 Added 8.66%
125,500 $7.93 Million
Q4 2018

Feb 14, 2019

BUY
$38.89 - $77.3 $93,336 - $185,520
2,400 Added 2.12%
115,500 $5.02 Million
Q3 2018

Nov 07, 2018

BUY
$71.81 - $90.15 $2.02 Million - $2.53 Million
28,100 Added 33.06%
113,100 $8.63 Million
Q2 2018

Aug 14, 2018

SELL
$48.54 - $85.31 $291,240 - $511,860
-6,000 Reduced 6.59%
85,000 $6.53 Million
Q1 2018

May 09, 2018

BUY
$44.33 - $58.52 $753,610 - $994,840
17,000 Added 22.97%
91,000 $4.64 Million
Q4 2017

Feb 07, 2018

BUY
$43.54 - $57.32 $609,560 - $802,480
14,000 Added 23.33%
74,000 $3.43 Million
Q3 2017

Nov 03, 2017

BUY
$49.79 - $66.32 $2.99 Million - $3.98 Million
60,000
60,000 $3.2 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.18B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Candriam S.C.A. Portfolio

Follow Candriam S.C.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.